VONCENTO

Reason for request

Clinical Benefit

Substantial	The AB of VONCENTO is : - substantial in the indication: “von Willebrand disease (VWD): Treatment of bleeding episodes or prevention and treatment of surgical bleeding in patients with von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.”
Insufficient	- insufficient in the indication “Haemophilia A (congenital factor VIII deficiency) : Prophylaxis and treatment of bleeding in patients with haemophilia A.

Clinical Added Value

no clinical added value	VONCENTO does not provide any improvement in actual benefit (IAB V, non-existent) in the current management of von Willebrand disease.
Not applicable	Haemophilia A : Not applicable